Aelis Farma
Biopharmaceutical company developing CB1 receptor inhibitors for CNS disorders.
AELIS | PA
Overview
Corporate Details
- ISIN(s):
- FR0014007ZB4
- LEI:
- 8945008D5R6WV7EXRN47
- Country:
- France
- Address:
- 1 RUE LAFAURIE DE MONBADON, 33000 BORDEAUX
- Website:
- https://www.aelisfarma.com
- Sector:
- Manufacturing
Description
Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-30 18:00 |
Informations privilégiées / Autres communiqués
|
French | 252.3 KB | ||
| 2024-01-17 18:23 |
Informations privilégiées / Autres communiqués
|
French | 265.9 KB | ||
| 2024-01-17 18:23 |
Inside Information / Other news releases
|
English | 267.5 KB | ||
| 2024-01-09 18:29 |
Inside Information / Other news releases
|
English | 280.1 KB | ||
| 2024-01-09 18:29 |
Informations privilégiées / Autres communiqués
|
French | 291.0 KB | ||
| 2024-01-03 19:00 |
Informations privilégiées / Autres communiqués
|
French | 391.6 KB | ||
| 2023-11-07 18:31 |
Informations privilégiées / Autres communiqués
|
French | 324.9 KB | ||
| 2023-11-07 18:31 |
Inside Information / Other news releases
|
English | 323.3 KB | ||
| 2023-09-27 19:07 |
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 232.8 KB | ||
| 2023-09-26 18:00 |
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise …
|
French | 233.7 KB | ||
| 2023-09-26 18:00 |
Half yearly financial reports and audit reports/limited reviews / Terms of avai…
|
English | 249.2 KB | ||
| 2023-09-25 18:00 |
Inside Information / News release on accounts, results
|
English | 335.1 KB | ||
| 2023-09-25 18:00 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 353.9 KB | ||
| 2023-08-29 18:00 |
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 253.8 KB | ||
| 2023-08-28 17:45 |
Inside Information / Other news releases
|
English | 296.2 KB |
Automate Your Workflow. Get a real-time feed of all Aelis Farma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aelis Farma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aelis Farma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
